BRISTOL MYERS SQUIBB CO files DEFA14A

This filing is a supplemental proxy statement for Bristol-Myers Squibb Company's 2026 Annual Meeting, providing information on proposals to be voted on, including the election of directors, advisory vote on executive compensation, approval of a stock award plan, ratification of the auditor, and a shareholder proposal. The meeting will be held virtually on May 5, 2026.